Sermorelin is studied to better understand growth hormone receptor signaling and the pituitary pathways that regulate natural GH release.

Sermorelin occupies a distinct position within the GHRH analog research toolkit. Where full-length analogs like Tesamorelin retain all 44 amino acids of native GHRH with N-terminal stability modifications, Sermorelin represents the truncated 1-29 fragment — the region identified as containing the complete receptor-binding pharmacophore of the GHRH sequence. This makes it a useful comparator compound in structure-activity studies examining which regions of the GHRH sequence are necessary and sufficient for GHRHR activation and downstream GH secretion signaling.

Its relatively compact molecular structure and well-characterized receptor binding profile have made Sermorelin one of the most extensively studied GHRH analogs in pituitary biology research. In somatotroph cell preparations, it reliably activates GHRHR-coupled cAMP signaling cascades, making it a reproducible and well-controlled reference compound for GH axis pharmacology assay design.

Beyond pituitary receptor biology, Sermorelin’s downstream GH and IGF-1 axis activation in preclinical models has driven research interest across metabolic signaling, neuroprotective pathway studies, and GH deficiency modeling in laboratory settings. All product is supplied exclusively for controlled laboratory settings and is not formulated for human or veterinary administration.

• CAS Number: 86168-78-7
• Molecular Weight: ~3357.9 g/mol
• Purity: ≥99%
• Also Known As: GHRH(1-29)-NH₂, GRF(1-29), Geref (pharmaceutical formulation — not supplied here), Sermorelin acetate (salt form in some preparations)
• Chemical Formula: C₁₄₉H₂₄₆N₄₄O₄₂S

In cell-based and preclinical models, Sermorelin binds to GHRHR on anterior pituitary somatotroph preparations, activating Gs-coupled adenylyl cyclase and driving intracellular cAMP accumulation. Downstream PKA activation triggers GH granule exocytosis and somatotroph transcriptional activity in a pattern consistent with native GHRH receptor stimulation. As a 29-amino acid fragment, Sermorelin engages the same receptor contact surface as full-length GHRH while offering a structurally simpler tool compound for isolating GHRHR-specific signaling events in assay systems.

GH release stimulated by GHRHR activation subsequently drives hepatic IGF-1 production through GH receptor-mediated JAK2/STAT5 signaling in target tissue preparations. This GH/IGF-1 axis cascade engages downstream PI3K/Akt and MAPK/ERK signaling in peripheral tissue models — pathways studied in the context of metabolic regulation, anabolic signaling, and neuroprotective pathway research in preclinical frameworks.

Compared to longer-acting GHRH analogs, Sermorelin’s shorter half-life in biological preparations — attributable to its lack of N-terminal stability modifications — makes it particularly useful for pulsatile GH secretion modeling and time-course studies where tight control over the duration of GHRHR stimulation is experimentally relevant.

• GHRHR Binding Kinetics and Receptor Pharmacology
• Pituitary Somatotroph cAMP Signaling Studies
• Pulsatile GH Secretion and Pulse Dynamics Modeling
• GH/IGF-1 Axis and JAK2/STAT5 Pathway Research
• GHRH Fragment Structure-Activity Studies
• Metabolic Signaling and GH-Dependent Pathway Research
• Neuroprotective Pathway and CNS Signaling Models